Risdiplam is the one orally administered drug approved to the treatment of SMA. It had been FDA permitted in 2020 to be used in people two months of age and older, and it features being an SMN2 gene splicing modifier bringing about higher levels of SMN protein. Oral administration is https://theodorq529cgj1.angelinsblog.com/profile